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Main Text 
Chronic non-bacterial osteomyelitis (CNO) is an inflammatory disorder of unknown aetiology 
characterised by painful sterile osteitis. It is also known as chronic recurrent multifocal 
osteomyelitis. Bone inflammation is followed by hyperostosis and osteolytic lesions, most 
commonly in the clavicles, long bones and spine [1]. Extra-osseous features include 
psoriasiform dermatoses such as palmoplantar pustulosis in approximately one-fifth of 
patients, as well as spondyloarthropathy and inflammatory bowel disease [2, 3]. The median 
age of onset of CNO is 10 years, although an adult-onset equivalent is known as SAPHO 
(synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome [2, 4]. Current understanding of 
the natural history of CNO is constrained by a lack of large prospective cohort studies. The 
available data suggest that approximately 20-35% of patients suffer long-term morbidity 
including growth retardation, bone deformities and kyphosis [5, 6]. As might be expected, 
such poor outcomes appear to be more common in children with longer periods of active 
inflammation due to delays in making the diagnosis of CNO, or disease that is refractory to 
current treatments [1, 6]. Therefore, as well as improving awareness of CNO among clinicians, 
there is also an urgent need to identify novel treatment approaches that reliably induce 
complete and sustained remission. Current treatments include non-steroidal anti-
inflammatory drugs which achieve remission in approximately 39% of patients, and 
bisphosphonates which achieve 51% [2]. There are also observational reports to support the 
use of targeted treatments such as therapeutic blockade of the innate cytokines TNF and 
IL1, although the molecular aetiology of CNO remains unknown [2]. Here, we outline the 
biological plausibility of using anti-17 therapy as a novel candidate treatment for CNO. 
 
An important feature of the bone tissue microenvironment is the tightly-regulated process of 
extracellular matrix turnover [7]. Bone resorption and remodelling is primarily performed by 
osteoclasts, multinucleated giant cells derived from haematopoietic stem cells [7]. 
Osteoclastogenesis is dependent on the conditioning of myeloid precursors with macrophage 
colony stimulating factor (M-CSF) and receptor activator of nuclear factor-kB ligand (RANKL) 
[7]. Osteoclast function (and RANKL expression) is upregulated by innate cytokines including 
TNF, IL1 and IL6 [7]. Although excessive osteoclast activity is the purported mechanism for 
the osteolytic lesions in CNO, this has not yet been specifically demonstrated. However, 
investigators have observed elevated innate cytokine production in patients with CNO that 
could drive osteoclastogenesis and excessive osteoclast activity (Fig. 1) [8]. For example, 
peripheral monocytes from treatment-naïve patients with CNO exhibit elevated TNF and 
IL1 (and diminished IL10) production compared with equivalent cells from healthy controls 
[9]. These observations have helped inform the prevailing theory that CNO is an 
autoinflammatory disorder involving disinhibited inflammasome activation. The 
inflammasome is an intracellular multiprotein complex that potentiates IL1 release and 
pyroptotic cell death in response to damage-associated molecular patterns and pathogens 
[10]. A receptor involved in activating the inflammasome, NLRP3, is highly expressed in 
monocytes and bone regions from patients with CNO [11]. Furthermore, the clinical 
phenotype of CNO is similar to that observed in monogenic autoinflammatory diseases 
featuring sterile osteitis such as Majeed syndrome and IL1RA deficiency [10]. However, no 
monogenic cause has been found for CNO and only 2.8% of patients report an affected family 
member [2]. This might be, in part, due to factors influencing epigenetic regulation such as 
the intestinal microbiome, as demonstrated in the pstpip2-/- mouse model of CNO [12]. In 
summary, experimental observations suggest that CNO is likely to have a complex aetiology 
that extends beyond the disinhibited inflammasome activation observed in high-penetrance 
monogenic autoinflammatory diseases. The presence of lymphocytic infiltrate in the chronic 
bony lesions of affected patients also raises the question whether CNO is caused by both 
autoinflammatory and autoimmune mechanisms, involving a final common pathway of 
lymphocyte-mediated inflammation with tissue specificity for skin, bones, and the intestine 
[11].    
 
Osteoclastogenesis and osteoclast activation is also dependent on IL17, produced by a subset 
of inflammatory CD4+ T cells known as Th17 cells, as well as mast cells and granulocytes [13, 
14]. Naïve CD4+ T cells are polarised into Th17 cells following exposure to IL6, IL23 and TGF. 
Although most Th17 cells reside within the gut mucosa where they regulate intestinal barrier 
immunity, this subset of T helper cells has diverse roles throughout the body including 
neutrophil recruitment and defence against extracellular pathogens including fungi [13]. Th17 
overexpression is implicated in autoimmune inflammatory diseases such as rheumatoid 
arthritis [13]. There are several reasons to suspect that IL17 may be an important driver of 
pathology in CNO (Fig. 1). First, IL6 (a major Th17-polarising cytokine) is found in high 
concentrations in the serum of patients with CNO and was the single most discriminative 
factor of 18 soluble mediators (IL17 was not studied) tested in differentiating CNO from a 
range of other inflammatory bone conditions as well as healthy individuals [8]. Second, the 
clinical spectrum of CRMO includes phenotypes such as psoriasis, palmoplantar pustulosis 
and ankylosing spondylitis, which are mediated by IL17 [2, 3, 14]. Finally, individuals with 
SAPHO syndrome exhibit significantly elevated peripheral Th17 cells compared with both 
healthy controls as well as patients with psoriasis [4]. Taken together, these observations 
suggest that the neutralisation of IL17 would be a plausible therapeutic strategy in CNO. 
  
The therapeutic application of IL17 blockade has proven highly effective in the treatment of 
psoriasis, and has also been used in patients with SAPHO syndrome  [13, 15]. Treatments 
include monoclonal antibodies directed against IL17A (secukinumab and ixekizumab) or 
against the IL17 receptor (brodalumab) [13]. These treatments are well tolerated and are not 
associated with significant adverse events [16]. A significant therapeutic response to anti-IL17 
therapies in patients with CNO would not only be of immediate benefit to patients but could 
potentially further our understanding of disease pathogenesis. Alongside IL17 blockade, other 
therapies targeting the IL6-IL23-Th17 axis should also be tested in CNO clinical efficacy trials 
including IL6 blockade (e.g. tociluzimab) which has been used previously [17], and IL23 
blockade which has been used in SAPHO syndrome [15]. We advocate that multicentre 
randomised placebo-controlled trials of such treatments should be conducted alongside 
prospective observation of patients with CNO. These studies should employ rigorous clinical 
data collection, whole genome sequencing, deep immunophenotyping and functional 
immunological evaluation, including the measurement of IL17 levels and the capacity for its 
production. Such collaborative research is the most likely way to understand the aetiology 








Fig. 1 Autoinflammatory cytokine production may result in CNO through IL17-mediated 
osteoclast activation. Increased inflammatory responsiveness of monocytes, macrophages 
and neutrophils is potentiated by unknown genetic/epigenetic mechanisms, resulting in 
chronic IL6-mediated expansion of the Th17 cell compartment and IL17 production. 
Overexpression of IL17 and innate cytokines drives excessive osteoclast activation and 
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